GE HealthCare Technologies (GEHC) EBITDA Margin (2022 - 2026)

GE HealthCare Technologies (GEHC) has reported EBITDA Margin for 5 consecutive years, with 13.96% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin rose 89.0% year-over-year to 13.96%; the trailing twelve-month figure through Jun 2026 stood at 12.86% (down 97.0% YoY), and the FY2025 full-year result was 13.4%, up 5.0% from the prior year.
• EBITDA Margin advanced to 13.96% in Q2 2026 per GEHC's latest filing, from 10.04% in the prior quarter.
• Across five years, EBITDA Margin topped out at 15.74% in Q4 2022 and bottomed at 10.04% in Q1 2026.
• Historically, EBITDA Margin has averaged 13.06% across 5 years, with a median of 13.11% in 2025.
• The sharpest annual moves came in 2024 and 2026: EBITDA Margin soared 182 bps in 2024, then slumped 313 bps in 2026.
• Over 5 years, EBITDA Margin stood at 15.74% in 2022, then dropped by 16 bps to 13.23% in 2023, then climbed by 14 bps to 15.06% in 2024, then retreated by 4 bps to 14.51% in 2025, then retreated by 4 bps to 13.96% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 13.96%, 10.04%, and 14.51% for Q2 2026, Q1 2026, and Q4 2025 respectively.